Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

AstraZeneca to Establish Predictive Science Center in St. Petersburg, Russia

By Pharmaceutical Processing | June 16, 2011

AstraZeneca announced today that it plans to establish a
Predictive Science Centre in St.
Petersburg over the coming year. The move strengthens
AstraZeneca’s investments in Russia
and supports the Russian Government’s strategy to modernize and develop the
country’s pharmaceutical sector.

The new AstraZeneca Predictive Science Centre, the company’s
first in Russia,
will leverage local scientific talent and focus on developing bioinformatics,
data analysis methods, software and systems to better predict the safety and
efficacy of potential new medicines. Approximately 30 people will work at the
Centre through collaborations with local companies and organizations as part of
a related agreement with the St. Petersburg
government to be announced later this week.

Earlier this year, the company began construction of a new
$150 million manufacturing facility in the Kaluga
region to supply Russia
with innovative AstraZeneca medicines that are locally manufactured. In addition,
AstraZeneca has established several partnerships with Russian development
institutes, including the Skolkovo Innovation Centre and Russia Venture
Company, to share its global R&D expertise through research collaborations,
grant programs, and clinical trials.

The new R&D and manufacturing investments, combined with
the growing operational sales and marketing capabilities and an increased
clinical research focus in Russia,
reinforce AstraZeneca’s long term commitment to the country and constitute a significant
contribution to the Russian economy of $1.2 billion over the next five years.

Speaking today at the St. Petersburg International Economic
Forum in Russia, David
Brennan, Chief Executive of AstraZeneca, said: “Russia is a dynamic economy where our
growing investments will help us to offer to patients AstraZeneca’s portfolio
of innovative medicines. We are pleased to contribute to the development of an
innovative healthcare sector through our local research and manufacturing
capabilities, established operations, and scientific and educational
collaborations.”

 

 

Related Articles Read More >

The blueprint for personalized biopharma
Sai Life Sciences opens dedicated veterinary-API unit alongside flagship Bidar site
This is the logo of Johnson & Johnson.
Johnson & Johnson commits $2B investment to North Carolina manufacturing facility
Bionova The Woodlands Texas pDNA facility (1)
Bionova opens new plasmid DNA materials production plant in Texas
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE